



CS/NSE&BSE/UFR/2019-20
August 14, 2019

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Stock Code: SUVEN–EQ

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001
Stock Code: 530239

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....


With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 14th August, 2019, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter ended 30th June, 2019.

We are enclosing herewith the following documents:

- a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter ended 30th June, 2019
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and
- c) A copy of the Press Release of our company

We request you to take these documents on your records. The Board Meeting commenced at 11:00 A.M. and concluded at 13:00 P.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**


K Hanumantha Rao
Company Secretary

Encl: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LTD

Regd. Off: SDE Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN-AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June' 2019

Rs. In Lakhs

Sl. No.	PARTICULARS	STANDALONE				CONSOLIDATED			
		For the Quarter Ended		For the year ended		For the Quarter Ended		For the year ended	
		30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited	30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited
1	Income								
	Revenue from operations	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.93	19,166.22	66,350.44
	Other Income	300.67	375.33	812.77	2,422.93	300.67	375.33	812.77	2,422.93
	Total income	20,199.30	25,705.27	19,978.99	68,773.37	20,199.30	25,705.26	19,978.99	68,773.37
2	Expenses								
	a) Cost of materials consumed	5,866.31	6,235.09	3,859.30	20,413.82	5,866.31	6,235.08	3,859.30	20,413.82
	b) Purchases of stock-in-trade	-	-	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,732.14)	1,302.19	2,595.82	(3,061.41)	(1,732.14)	1,302.19	2,595.82	(3,061.41)
	d) Employee benefits expenses	1,875.41	1,739.22	1,714.82	6,347.79	1,942.44	1,809.92	1,775.98	6,612.45
	e) Finance costs	130.75	157.49	106.79	376.31	168.72	157.82	107.04	377.38
	f) Depreciation and amortisation expense	555.03	546.26	550.81	2,214.05	555.03	546.26	550.81	2,214.05
	g) Manufacturing Exps	2,534.68	2,499.40	2,285.50	9,982.32	2,534.68	2,499.40	2,285.50	9,982.32
	h) R & D Exps	1,310.14	1,786.89	1,598.87	6,027.60	4,285.71	4,702.99	2,775.79	11,985.07
	i) Other Expenses	1,040.96	1,237.68	1,288.81	4,286.59	1,057.26	1,257.29	1,332.27	4,375.37
	Total expenses	11,581.14	15,504.22	14,000.72	46,587.07	14,678.01	18,510.95	15,282.51	52,899.05
3	Profit before exceptional items & Tax (1-2)	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
4	Exceptional Items	-	-	-	-	-	-	-	-
5	Profit before Tax (3-4)	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
6	Tax Expenses								
	a) Current tax	3,483.61	2,143.99	1,249.14	4,604.23	3,483.61	2,143.99	1,249.14	4,604.23
	b) Deferred tax	(583.22)	1,259.22	844.92	2,575.78	(583.22)	1,259.22	844.92	2,575.78
7	Net Profit/ (Loss) for the period/year(5-6)	5,717.77	6,797.84	3,884.21	15,006.29	2,620.90	3,791.10	2,602.42	8,694.31
8	Other Comprehensive Income								
8.a	(i) Items that will not be reclassified to profit or loss	(5.29)	10.59	(10.58)	(21.16)	(5.29)	10.59	(10.58)	(21.16)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.85	(3.70)	3.66	7.39	1.85	(3.70)	3.66	7.39
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-
	Total other Comprehensive Income	(3.44)	6.89	(6.92)	(13.77)	(3.44)	6.89	(6.92)	(13.77)
9	Total Comprehensive Income for the period (7+8)	5,714.33	6,804.73	3,877.29	14,992.52	2,617.46	3,797.99	2,595.50	8,680.54
10	Paid-up equity share capital	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	103,802.33	84,178.15	89,274.45	98,088.00	84,178.15	81,826.56	78,054.80	81,826.56
12	Earning Per Share (EPS) (Face value of Rs.1/- each)								
	a) Basic	4.49	5.34	3.05	11.79	2.06	2.98	2.04	6.83
	b) Diluted	4.49	5.34	3.05	11.79	2.06	2.98	2.04	6.83
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES

0

PARTICULARS	STANDALONE				CONSOLIDATED			
	For the Quarter Ended			For the year Ended	For the Quarter Ended			For the year Ended
	30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited	30/06/2019 Un-Audited	31/03/2019 Audited	30/06/2018 Un-Audited	31/03/2019 Audited
1 SEGMENT REVENUE :-								
a) Manufacturing (CRAMS)	19,616.35	23,742.62	18,024.22	61,362.91	19,616.35	23,742.62	18,024.22	61,362.91
b) Services (DDDSS)	282.28	1,587.32	1,142.00	4,987.53	282.28	1,587.32	1,142.00	4,987.53
c) Research & Development	-	-	-	-	-	-	-	-
TOTAL	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.94	19,166.22	66,350.44
Less Inter segment Revenue	-	-	-	-	-	-	-	-
Net Sales from Operations	19,898.63	25,329.94	19,166.22	66,350.44	19,898.63	25,329.94	19,166.22	66,350.44
2 SEGMENT RESULTS :-								
Profit/(Loss) before tax and interest:								
a) Manufacturing (CRAMS)	10,587.58	12,117.59	7,086.74	26,594.91	10,587.57	11,851.99	7,025.59	26,330.25
b) Services (DDDSS)	60.20	570.44	761.15	2,558.00	60.20	821.14	758.56	2,551.33
c) Research & Development	(1,310.15)	(1,786.89)	(1,598.88)	(6,027.60)	(4,367.88)	(4,702.99)	(2,775.79)	(11,985.07)
TOTAL	9,337.63	10,901.14	6,249.01	23,125.31	6,279.89	7,970.14	5,008.36	16,896.51
Less: i) Interest	46.41	69.59	35.97	199.02	84.05	69.59	35.97	199.02
ii) Other Un-allocable expenditure/(Income), net	673.06	630.50	234.77	739.99	674.55	706.24	275.91	823.17
Total Profit Before Tax	8,618.16	10,201.05	5,978.27	22,186.30	5,521.29	7,194.31	4,696.48	15,874.32
3 SEGMENT ASSETS :								
a) Manufacturing (CRAMS)	72,577.41	69,666.60	48,587.81	69,666.60	71,575.12	69,668.49	48,306.00	69,668.49
b) Services (DDDSS)	5,629.15	5,687.52	4,339.17	5,687.52	5,604.44	5,687.52	4,329.43	5,687.52
c) Research & Development	2,918.73	3,022.45	2,784.33	3,022.45	4,055.30	3,022.45	3,094.30	3,022.45
d) Un allocated	43,436.44	39,125.31	50,187.02	39,125.31	28,605.45	25,510.28	39,450.85	25,510.28
TOTAL	124,561.73	117,501.88	105,898.33	117,501.88	109,840.31	103,888.74	95,180.58	103,888.74
SEGMENT LIABILITIES :								
a) Manufacturing (CRAMS)	11,100.58	9,189.76	9,053.42	9,189.76	8,798.99	9,912.30	8,700.72	9,912.30
b) Services (DDDSS)	273.05	641.72	315.25	641.72	216.43	688.83	303.33	688.83
c) Research & Development	1,610.78	1,592.07	1,323.46	1,592.07	9,118.52	3,388.76	2,195.85	3,388.76
d) Un allocated	1,197.17	829.03	867.09	829.03	950.40	910.98	861.23	910.98
TOTAL	14,181.58	12,252.58	11,559.22	12,252.58	19,084.34	14,900.87	12,061.13	14,900.87

1) The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th August, 2019 and the same has been reviewed by the Statutory Auditors.

2) An Investment of USD 35.00 Million, 25% stake, in Rising Holdings Inc, (formerly known as Shore Suven pharma Inc) was made during April 2019, through our wholly owned subsidiary Suven Pharma Inc. The acquisition of Assets and Liabilities are under US court supervised process of Sec 363 of U.S. Bankruptcy code. As the Assets and Liabilities valuation is under process and the business operations are yet to commence, the company did not consider Rising Holdings Inc. for the consolidation.

3) The figures for the Qtr ended 31/03/2019 are the balancing figures in respect of the full financial year and unaudited published year to date figures up to the third Qtr of the relevant financial year.

4) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD



Venkat Jasti
 VENKAT JASTI
 Chairman & CEO
 DIN: 00278028

Place: Hyderabad
 Date: 14th Aug' 2019



TUKARAM & CO LLP

CHARTERED ACCOUNTANTS

Phones : 2322 1536

: 2322 8785

: 2322 8086

Ref No.LR/SLSL01/2019-20

Independent Auditor's Review Report on Standalone Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED


We have reviewed the accompanying statement of standalone unaudited financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter ended June 30, 2019 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').


This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)


(RAJENDER REDDY K)
PARTNER
M.No.231834
UDIN: 19231834AAAACD7962



Place: Hyderabad
Date: August 14, 2019



Ref No.LR/SLSL02/2019-20

Independent Auditor's Review Report on the Consolidated Unaudited Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial results of SUVEN LIFE SCIENCES LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income/loss of its associate, for the quarter ended June 30, 2019 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation'), read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular'). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended June 30, 2018 and quarter ended March 31, 2019 as reported in these unaudited consolidated financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.


3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Pharmaceuticals Limited	Wholly Owned Subsidiary
Suven Neuro Sciences Inc	Wholly Owned Subsidiary
Suven Pharma Inc	Wholly Owned Subsidiary
Rising Holdings Inc	Associate

14/08/2019



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial statements of USA branch of parent included in the standalone Ind AS financial statements of the Company whose financial statements reflect total assets of Rs.5.80 lakhs as at 30th June, 2019 and total revenue of Rs.-Nil- for the quarter ended on that date. The financial statements of this branch have been audited by the branch auditor, whose reports have been furnished to us, and our opinion in so far as it relates to the amounts and disclosures included in respect of these branches, is based solely on the report of such branch auditor.

We did not review the Ind AS financial statements of two subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs.24,103.53 lakhs as at 30th June 2019, total revenue of Rs.Nil ,total expenses of Rs.3,096.45 lakhs and total net loss after tax of Rs.3,096.45 lakhs for the quarter ended on that date, as considered in the consolidated financial results. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.


7. We draw your attention to Note No. 2 in the statement regarding preparation of financial results, that the Company has invested thirty five million US Dollars in Rising holdings Inc through its wholly owned subsidiary, Suven Pharma Inc, during April, 2019.As per explanation provided by the management it is understood that the acquisition of assets and liabilities process is going on and business operations are yet to commence, hence company did not consider Rising Holdings Inc for the consolidation.

Our conclusion on the statement is not modified in respect of the above matter.

For **TUKARAM & CO LLP**
Chartered Accountants
(Firm Registration No.004436S)



(RAJENDER REDDY K)
P A R T N E R
M.No.231834
UDIN:19231834AAAACE1511



Place: Hyderabad
Date: August 14, 2019

14/08/2019

News Release

Suven's Income at Rs. 2020 Mn; PAT at Rs. 571 Mn for the quarter ended June 2019

HYDERABAD, INDIA (August 14, 2019) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30th June 2019. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th August, 2019 at Hyderabad.

Financial Highlights for the 1st Quarter ended June' 2019: (QoQ)

Growth in revenue	INR 2020 Mn vs. INR 2570 Mn - Down by 21.42%
Growth in PAT	INR 571 Mn vs. INR 680 Mn - Down by 16.02%
Growth in EBIDTA	INR 930 Mn vs. INR 1090 Mn - Down by 14.68%

Financial Highlights (comparison with same quarter, previous year):

Growth in revenue	INR 2020 Mn vs. INR 1998 Mn - Up by 1.10%
Growth in PAT	INR 571 Mn vs. INR 388 Mn - Up by 47.38%
Growth in EBIDTA	INR 930 Mn vs. INR 664 Mn - Up by 40.21%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 131 Mn (6.49% on revenue) for the quarter ended 30th June 2019.

Update on patents during this period can be viewed at:

<http://suven.com/Patentupdates.aspx>

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com